生产企业：Astellas Pharma
ASP-4396 (also known as ASP4396) is a KRAS G12D-targeted protein degrader developed by Astellas Pharma. It reached Phase 1 clinical testing before being discontinued. Astellas subsequently advanced a follow-up candidate, setidegrasib (ASP3082), which is currently in Phase 3 clinical trials for non-small cell lung cancer (NSCLC) and pancreatic cancer.
ASP-4396 (also known as ASP4396) is a KRAS G12D-targeted protein degrader developed by Astellas Pharma. It reached Phase 1 clinical testing before being discontinued. Astellas subsequently advanced a follow-up candidate, setidegrasib (ASP3082), which is currently in Phase 3 clinical trials for non-small cell lung cancer (NSCLC) and pancreatic cancer.
ASP-4396 is a KRAS G12D-targeted protein degrader developed by Astellas Pharma.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
